(0.78%) 5 074.84 points
(1.13%) 38 242 points
(1.13%) 15 834 points
(-3.38%) $79.16
(-2.51%) $1.941
(0.84%) $2 322.30
(1.72%) $27.11
(1.59%) $963.30
(-0.45%) $0.933
(-0.61%) $11.03
(-0.32%) $0.798
(-0.48%) $93.00
Quarter results today
(amc 2024-05-01)
Expected move: +/- 4.94%
Live Chart Being Loaded With Signals
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases...
Stats | |
---|---|
今日成交量 | 255 806 |
平均成交量 | 502 818 |
市值 | 5.09B |
EPS | $0 ( 2024-02-21 ) |
下一个收益日期 | ( $-0.580 ) 2024-05-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -36.49 |
ATR14 | $0.155 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Hoffmeister David F | Buy | 10 000 | Common Stock |
2024-04-10 | Hoffmeister David F | Sell | 10 000 | Stock Option (Right to Buy) |
2024-04-08 | Gilliam Joseph E | Buy | 59 801 | Common Stock |
2024-04-08 | Gilliam Joseph E | Sell | 10 456 | Common Stock |
2024-04-08 | Gilliam Joseph E | Sell | 41 068 | Common Stock |
INSIDER POWER |
---|
0.86 |
Last 100 transactions |
Buy: 501 923 | Sell: 495 631 |
音量 相关性
Glaukos Corp 相关性 - 货币/商品
Glaukos Corp 财务报表
Annual | 2023 |
营收: | $314.71M |
毛利润: | $239.14M (75.99 %) |
EPS: | $-2.78 |
FY | 2023 |
营收: | $314.71M |
毛利润: | $239.14M (75.99 %) |
EPS: | $-2.78 |
FY | 2022 |
营收: | $282.86M |
毛利润: | $213.88M (75.61 %) |
EPS: | $-2.09 |
FY | 2021 |
营收: | $294.01M |
毛利润: | $227.38M (77.34 %) |
EPS: | $-1.070 |
Financial Reports:
No articles found.
Glaukos Corp
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。